MIRA PHARMACEUTICALS, INC. (MIRA) Stock Price, Financials & Summary

Price chart

Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29

Key dataOct 29, 2026

Open$0.57

From 52W high−65.95%

Volume321802.00

Market cap$24.32M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 29, 2026

Open

$0.57

From 52W high

−65.95%

Volume

321802.00

Market cap

$24.32M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.7x

P/E (TTM)

—

RSI (14)

38.4

MomentumView details →

1D Return

+4.08%

YTD Return

−61.17%

SummaryUpdated Jun 1, 2026

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Baltimore, Maryland. The company went public in August 2023 and focuses on developing novel synthetic cannabinoid therapies for neurological and psychiatric conditions. MIRA was formerly known as MIRA1a Therapeutics, Inc. before its corporate restructuring and public listing. As a pre-revenue biotech company, MIRA is currently in the clinical development phase with its lead drug candidate targeting anxiety and cognitive decline associated with early-stage dementia.

Ask drillr about MIRA PHARMACEUTICALS, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.7x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

3.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−116.14%

ROA (TTM)

−115.56%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

+23.66%

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

−63.69%

MomentumView details →

1D Return

+4.08%

YTD Return

−61.17%

1Y Return

−64.46%

RSI (14)

38.4

vs 50D SMA

−20.84%

vs 200D SMA

−39.50%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

200.08x

Quick Ratio

200.08x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.03

EPS Surprise

—

Beats (12Q)

4/12

Next Q EPS Est

−$0.03

Avg Surprise (4Q)

55.27%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−9.48M

Op. CF (TTM)

−4.64M

Next earningsDec 2, 2026 →

Latest newsMore news →

MIRA PHARMACEUTICALS, INC. reported that oral SKNY-1 reduced weight and fat in obese mice and showed favorable lean-mass and weight-regain outcomes compared with semaglutide.5h ago

MIRA Pharmaceuticals reported positive results from a 21-day preclinical study in which oral MIRA-55 demonstrated significant pain relief comparable to Celebrex in a chronic inflammatory pain model.7d ago

Similar companies

Scilex Holding CompanySCLX Citius Oncology, Inc.CTOR Modern Chinese Medicine Group Co., Ltd.01643.HK Bristol-Myers Squibb Company CeCELG-RI Beijing Biostar Pharms Co Ltd02563.HK TYK Medicines, Inc02410.HK Find similar companies →

Latest newsMore news →

MIRA PHARMACEUTICALS, INC. reported that oral SKNY-1 reduced weight and fat in obese mice and showed favorable lean-mass and weight-regain outcomes compared with semaglutide.5h ago MIRA Pharmaceuticals reported positive results from a 21-day preclinical study in which oral MIRA-55 demonstrated significant pain relief comparable to Celebrex in a chronic inflammatory pain model.7d ago